RTP Mobile Logo
Addressing Current Questions and Controversies in the Management of Lymphoma and Chronic Lymphocytic Leukemia
Released March 2018

Proceedings from Part 1 of a 2-part satellite symposia series during the 59th ASH Annual Meeting. Featuring perspectives from Drs Martin Dreyling, Jonathan W Friedberg, Craig Moskowitz, Owen A O'Connor and Laurie H Sehn. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma and chronic lymphocytic leukemia (CLL).

    Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 174,250 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2018, and 56,100 individuals will die from these diseases. Importantly, nearly 70 drug products are currently labeled for use in the management of hematologic cancers with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of their appropriate application across a vast spectrum of tumor types. This is particularly true within the realm of Hodgkin and non-Hodgkin lymphoma, including CLL, where the past several years have yielded a staggering number of important clinical and research advances.

    These proceedings from a CME symposium during the ASH Annual Meeting use the perspectives of a group of community oncologists gathered during a daylong working group to establish and subsequently address some of the most frequently encountered questions and controversies facing clinicians involved in the management of these diseases. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma, including CLL, with the formulation of up-to-date clinical management strategies.


    • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed and relapsed/refractory (R/R) CLL, considering the patient’s clinical presentation, biomarker profile and psychosocial status.
    • Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and R/R diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.
    • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
    • Assess the benefits and risks of evidence-based systemic treatment options to individualize and optimize the care of patients with T-cell lymphoma.
    • Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immune checkpoint inhibitors for the treatment of HL and non-Hodgkin lymphoma (NHL) to determine the current and/or potential utility of each in clinical practice.
    • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with R/R B-cell cancers for whom this approach may be appropriate.
    • Assess the ongoing clinical trials evaluating other novel investigational approaches for HL, NHL and CLL, and obtain consent from appropriate patients for study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Martin Dreyling, MD, PhD
    Professor of Medicine
    Department of Medicine III
    University Hospital – LMU Munich
    Munich, Germany

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Roche Laboratories Inc; Other Remunerated Activities: Celgene Corporation, Janssen Biotech Inc, Mundipharma International Limited, Roche Laboratories Inc.

    Jonathan W Friedberg, MD, MMSc
    Samuel E Durand Professor of Medicine
    Director, James P Wilmot Cancer Institute
    University of Rochester
    Rochester, New York

    Data and Safety Monitoring Board: Bayer HealthCare Pharmaceuticals.

    Craig Moskowitz, MD
    Stephen A Greenberg Chair in Lymphoma Research
    Clinical Director, Division of Hematologic Oncology
    Attending Physician, Lymphoma and Adult BMT Services
    Member, Memorial Sloan Kettering Cancer Center
    Professor of Medicine, Weill Medical College of Cornell University
    New York, New York

    Consulting Agreements: Celgene Corporation, Genentech BioOncology, Merck, Seattle Genetics; Contracted Research: Merck, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics.

    Owen A O’Connor, MD, PhD
    Professor of Medicine and Developmental Therapeutics
    Director, Center for Lymphoid Malignancies
    Columbia University Medical Center
    College of Physicians and Surgeons
    NewYork-Presbyterian Hospital
    New York, New York

    Consulting Agreements: Celgene Corporation, Mundipharma International Limited; Contracted Research: Celgene Corporation, Mundipharma International Limited, Spectrum Pharmaceuticals Inc.

    Laurie H Sehn, MD, MPH
    Centre for Lymphoid Cancer
    BC Cancer Agency and University of British Columbia
    Vancouver, British Columbia, Canada

    Consulting Agreements: AbbVie Inc, Amgen Inc, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Janssen Biotech Inc, Roche Laboratories Inc, Seattle Genetics, Takeda Oncology.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: March 2018
    Expiration date: March 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):